{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:14:29Z","timestamp":1784308469522,"version":"3.55.0"},"reference-count":11,"publisher":"Massachusetts Medical Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2024,3,7]]},"DOI":"10.1056\/nejme2400311","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T22:01:12Z","timestamp":1709762472000},"page":"944-946","source":"Crossref","is-referenced-by-count":12,"title":["Enfortumab Vedotin and Pembrolizumab \u2014 A New Perspective on Urothelial Cancer"],"prefix":"10.1056","volume":"390","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-8691","authenticated-orcid":false,"given":"G\u00fcnter","family":"Niegisch","sequence":"first","affiliation":[{"name":"From the Department of Urology, University Hospital and Medical Faculty of the Heinrich Heine University D\u00fcsseldorf, and the Center for Integrated Oncology (CIO) D\u00fcsseldorf, D\u00fcsseldorf, and the CIO Aachen\u2013Bonn\u2013Cologne\u2013D\u00fcsseldorf, Cologne \u2014 all in Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)48996-8"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30541-6"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"issue":"11","key":"e_1_3_3_11_2","article-title":"Healthcare costs associated with first-line (1L) treatment of patients with locally advanced or metastatic urothelial carcinoma (la\/mUC) in the United States (US).","volume":"19","author":"Ike C","year":"2023","unstructured":"Ike C, Kongnakorn T, Tichy E, Benedict A, Alvarez JS, Kearney M. Healthcare costs associated with first-line (1L) treatment of patients with locally advanced or metastatic urothelial carcinoma (la\/mUC) in the United States (US). JCO Oncol Pract 2023;19(11):Suppl (https:\/\/ascopubs.org\/doi\/abs\/10.1200\/OP.2023.19.11_suppl.11).","journal-title":"JCO Oncol Pract"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.673"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMe2400311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:46:11Z","timestamp":1749681971000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMe2400311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,3,7]]}},"alternative-id":["10.1056\/NEJMe2400311"],"URL":"https:\/\/doi.org\/10.1056\/nejme2400311","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}